Annual Accounts Receivable
$206.44 M
+$198.72 M+2571.70%
31 December 2023
Summary:
Apellis Pharmaceuticals annual accounts receivable is currently $206.44 million, with the most recent change of +$198.72 million (+2571.70%) on 31 December 2023. During the last 3 years, it has risen by +$206.44 million (+100.00%). APLS annual accounts receivable is now at all-time high.APLS Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$279.01 M
-$25.42 M-8.35%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly accounts receivable is currently $279.01 million, with the most recent change of -$25.42 million (-8.35%) on 30 September 2024. Over the past year, it has increased by +$109.75 million (+64.84%). APLS quarterly accounts receivable is now -8.35% below its all-time high of $304.43 million, reached on 30 June 2024.APLS Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2571.7% | +64.8% |
| 3 y3 years | +100.0% | +7821.9% |
| 5 y5 years | - | - |
APLS Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | -8.3% | +7821.9% | |
| 5 y | 5 years | at high | -8.3% | ||
| alltime | all time | at high | -8.3% |
Apellis Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $279.01 M(-8.4%) |
| June 2024 | - | $304.43 M(+13.7%) |
| Mar 2024 | - | $267.84 M(+29.7%) |
| Dec 2023 | $206.44 M(+2571.7%) | $206.44 M(+22.0%) |
| Sept 2023 | - | $169.26 M(+52.6%) |
| June 2023 | - | $110.91 M(+252.0%) |
| Mar 2023 | - | $31.50 M(+307.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $7.73 M(-23.5%) | $7.73 M(-4.5%) |
| Sept 2022 | - | $8.09 M(+7.6%) |
| June 2022 | - | $7.52 M(+18.8%) |
| Mar 2022 | - | $6.33 M(-37.3%) |
| Dec 2021 | $10.10 M(>+9900.0%) | $10.10 M(+186.9%) |
| Sept 2021 | - | $3.52 M(+389.8%) |
| June 2021 | - | $719.00 K(>+9900.0%) |
| Dec 2020 | $0.00 | $0.00 |
FAQ
- What is Apellis Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual accounts receivable year-on-year change?
- What is Apellis Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Apellis Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of APLS is $206.44 M
What is the all time high annual accounts receivable for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual accounts receivable is $206.44 M
What is Apellis Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, APLS annual accounts receivable has changed by +$198.72 M (+2571.70%)
What is Apellis Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of APLS is $279.01 M
What is the all time high quarterly accounts receivable for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly accounts receivable is $304.43 M
What is Apellis Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, APLS quarterly accounts receivable has changed by +$109.75 M (+64.84%)